Publicidad
Educación continua 03 de agosto de 2011

Conceptualizando VI: Comportamiento de la glucosa y la 18F-FDG en tumores malignos, con enfoque en tumores de cabeza y cuello

Referenciar Imprimir Descargar PDF

Referencias

  1. van der Waal I, de Bree R, Brakenhoff R, Coebergh JW. Early diagnosis in primary oral cancer: is it possible? Med Oral Patol Oral Cir Bucal 2011;16:e300-5.
  2. Begg AC, Haustermans K, Hart AA, Dische S, Saunders M, Zac-krisson B et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 1999;50:13-23.
  3. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997;65:284-97.
  4. Fcinmesser R, Freeman JL, Noyek AM, Birt D. Metastatic neck disease: a clinical/ radiographic/ pathologic correlative study. Arch Otolaryngol Head Neck Surg 1987;113:1307-10.
  5. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am 2005;43:189-204.
  6. Schantz SP, Harrison LB, Hong WK. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity and oropharynx. In: Devita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Philadelphia: JB Lippincon;1993. pp. 574-630.
  7. Jarret WFH. Environmental carcinogens and papillomaviruses in the pathogenesis of cancer. Proc R Soc Lond B Bioi Sci 1987;231:1-11.
  8. Gilison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744-54.
  9. Hoffman M, Gorogh T, Gottschlich S, et al. Human papillomaviruses in head and neck cancer: 8 year-survival-analysis of 73 patients. Cancer Lett 2005;218:199-206.
  10. Ragin C, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta-analysis. Int J Cancer 2007;121:1813-20.
  11. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol 2009;27:2509-15.
  12. Lodish et al. Biología celular y molecular. Buenos Aires: Ed. Médica Panamericana 2005. Volver.
  13. Sasaki K, Murakami. T, Kawasaki M, Takahashi M. Theceilcycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-84.
  14. van Dierendonck JH, Keijzer R, van de Velde CJH. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 1989;49:2999- 3006.
  15. Friedlander ME, Hedley DW, Taylor JW. Clinical and biological significance of aneuploidy in human tumors. J Clin Pathol 1984;37:961-74.
  16. Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer 1990;65:1194-205.
  17. Atkm NB, Kay R. Prognostic significance of modal DNA values and other factors in malignant tumors, based on 1465 cases. Br J Cancer 1979;:40:210-22.
  18. Belbin TJ, Singh B, Barber I, Socci N, Wenig B, Smith R, et al. Molecular classification of head and neck squamous cell carcinoma usingc DNA microarrays. Cancer Res 2002;62:1184–90.
  19. Martí-Bonmatí L, Sopena R. Los receptores y los marcadores: hacia la ciencia de la imagen a través de las hibridaciones. Radiología 2007;49:299-304.
  20. Minn H, Joensuu H, Ahonen A, Kiemi P. Fluoro-deoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-81.
  21. DiChiro G, DeLaPaz R, Brooks R, et aI. Glucose utilization of cerebral gliomas measured by (18F)fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
  22. Mineura K, Yasuda T, Kowada M, ShLshido F, Ogawa T, Uemura K. Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurologica Res 1986;8:164-8.
  23. Alavi JB, Alavi A, Chawtuk J, Kushner M, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074-8.
  24. Lodish H, Baltimore D, Berk A. Molecular cell biology. Third ed. Vol.1. Scientific American Books, New York 1995.
  25. Brostoff J, Scadding G, Male D, Roitt I. Inmunología clínica. Gower Medical Publishing ed. Vol. 1., London 1964.
  26. Pardo Mindán J, Panizo A, Martínez L. Valoración del sistema de polímeros de dextrano. En: Vision (PDE) en la detección inmunohistoquímica. Revista Española Patología 1998;31:9-16.
  27. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int. J. Cancer 1999;80:194–8.
  28. Burant CF, Takeda J, Brot-Laroche E, Bell GI, Davidson NO. Fructose transporter in human spermatozoa and small intestine in GLUT5 transporter. J Biol Chem 1992;267:14523–6.
  29. Gould GW, Holman GD. The glucose transporter family: structure, function and tissue-specific expression. Biochem J 1993;295:329–41.
  30. Miller JH, Mullin JM, McAvoy E, Kleinzeller A. Polarity of transport of 2-deoxy-D-glucose and D-glucose by cultured renal epithelia (LLC-PK1). Biochim Biophys Acta 1992;1110:209–17.
  31. Rocha F, Malagoli R, Cándido K, Lopes Carvalho A, Werneck da Cunha I, Lourenço SV, Soares FA. Glut1 and Glut3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 2010;15:2374-87.
  32. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113–7.
  33. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18–24.
  34. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–15.
  35. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941–3.
  36. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139–68.
  37. Schoder H, Fury M. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nuc Med 2009;50:74S-88S.
  38. Arias de la Vega F, Garcia–Velloso MJ. Estado actual del PET en los tumores de cabeza y cuello: Impacto en la planificación del tratamiento radioterápico. Anales Sis San Navarra 2009;32.
  39. Naumov GN, Akslen LA. Role of angiogenesis in human tumor dormancy: animal models of the angiogenesis switch. Cell Cycle 2006;5:1779-87.
  40. Watanabe A, Tanaka R, Takeda N, Washiyama K. DNA synthesis, blood flow, and glucose utilization in experimental rat brain tumors. J Neurosurg 1989;70:86-91.
  41. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-55.
  42. Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, Overgaard J. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923-31.
  43. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
  44. Mizukami Y, Kohgo Y. Hypoxia inducible factor–1: independent pathway in tumor angiogenesis .Clin Cancer Res 2007;13:5670-4.
  45. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
  46. Kyzas PA, Stefanou D. Prognostic significance of VEGF inmunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2005;131:624-30.
  47. Kyzas PA, Stefanou D. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta analysis. Clin Cancer Res 2005;11:1434-40.
  48. Riedel F. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy. Adv Otorhinolaryngol 2005;62:103–20.
  49. Eiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008;35:274-85.
  50. Bozec A, Gros FX. Vertical VEGF Targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer 2008;44:1922-30.
  51. Bozec A, Sudaka A. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer8orthotopic model. Br J Cancer 2008;99:93-9.
  52. Mena E, Turkbey I. A novel PET imaging approach for detection of tumor angiogenesis via the expression of vβ3 integrin using an RGD peptide, [18F]fluciclatide (AH111585). J Nucl Med 2010;51(Suppl2):505.
  53. Villalobo A, Palomo-Jiménez PI, Ruano MJ. El receptor del factor de crecimiento epidérmico. Vitae: Academia Biomédica Digital, Nº. 5, 2000.
  54. Schlessinger J, Shreiber AB, Levi A, Liberman T, Yarden Y. Regulation of cell proliferation by epidermal growth factor. Crit Rev Biochem 1983;2:93-111.
  55. Gullick WR. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancer. B Med Bull 1991;47:87-98.
  56. Heisiger EM, Hayes IR, Pierz DM, Budzilovich GN. Pronostic relevance of epidermal growth factor receptor (EGF-R) and C-Neulerb B2 expression in Glioblastomas (GB Ms). J Neuro-oncol 1993;16:93-104.
  57. Ozanne B, Richards CS, Haudler F, Burns D, Gusterson B. Over expression of the EGF receptor in a hallmark of squamous cell carcinomas. J Pathol 1986;149:9-14.
  58. Neal DE, Shaiples L, Smith K, Feunelly J, Hall RR, Havis A. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619-25.
  59. Bargmarm CI, Hung MC, Weinherg RA. Multiple independent activations of the new oncogene by a point mutation altering the transmembrane domain of P 185. Cell 1986;45:649-85.
  60. Psyrri A, Weinberger PM. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005;11:5856-62.
  61. Burtness B, Goldwater MA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastasic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-54.
  62. Vermorken JB, Mesia R. Platinum–based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
  63. Muthukrishnan A, Mountz J, Grandis J, Lai S. FDG PET-CT accurately assesses response to intratumoral epidermal growth factor receptor (EGFR) antisense (AS) DNA therapy in recurrent squamous cell carcinoma of the head and neck (SCCHN). J Nucl Med 2007;48 (Suppl 2):150P.
  64. Cruz T, Oliva JP, Borrón M, Pimentel G. Importancia del diagnóstico inmunogamagráfico con el antirreceptor del factor de crecimiento epidérmico en carcinomas de cabeza y cuello. Rev Cubana Oncol 1999;15:160-4.
  65. Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gönen M, et al. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release 2011;149:292-8.
  66. Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing non-small cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A. 2011;108:1603-8.